Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:17:04.458Z.
Consensus retrieved: 2026-10-06T12:31:15.408Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:04.458Z.
Quote observation: 2026-10-06T14:15:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Forward PE Ratio (N/A) = Dated Quote Price ($1.90) / Consensus Forward EPS ($-0.55)
FORWARD PE RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$120.68M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $120.68M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $119.64M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.61M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.58M | N/A |
| Genelux Corporation (GNLX)vs › | $117.54M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $115.16M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.10M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $127.42M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.90, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.55 | $-0.57 – $-0.53 | 3 | n/m |
| 2027-12-31 | $-0.61 | $-0.66 – $-0.55 | 3 | n/m |
| 2028-12-31 | $0.02 | $-0.08 – $0.07 | 3 | 94.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
